594 - An Open-Label Study in Healthy Volunteers to Determine the Absolute Bioavailability of, the Effect of Food and Dosing by Nasogastric Tube upon the Pharmacokinetics of a Single Oral Dose of Olorofim (OLO)

Thursday, October 20, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

PN

Paul A. Newell, MB BS

F2G
Manchester, England, United Kingdom
John H. Rex, MD

Chief Medical Officer
F2G, Limited
WELLESLEY HILLS, MA, United States
HG

Hal Galbraith, PharmD

Senior Director, Clinical Pharmacology
IQVIA
Lees Summit, Missouri, United States
SI

Samuel Israel, MBBS

LabCorp CRU
leeds, England, United Kingdom
JB

James Bush, MB ChB, PhD

VP Medical Services
Labcorp
Leeds, England, United Kingdom